carbidopa

Carbidopa (Lodosyn) is an aromatic-L-amino-acid decarboxylase inhibitor (IC50: 29±2 μM). It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA.

Carbidopa hydrochloride is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa. This property is significant in that it allows a greater proportion of peripheral levodopa to cross the blood–brain barrier for central nervous system effect.

Carbidopa-CoA (Carbidopa-coenzyme A) is a derivative of coenzyme A.

Carbidopa monohydrate (S(-)-Carbidopa) is an inhibitor of DOPA decarboxylase, preventing the conversion of levodopa to dopamine.

Foscarbidopa is a prodrug of carbidopa, which is metabolised by alkaline phosphatase into carbidopa upon entering the body, thereby increasing dopamine levels. It is often used in combination with levodopa to treat motor complications in advanced Parkinson's disease.

L-DOPA (Levodopa) is an orally active metabolic precursor of the neurotransmitter dopamine. It can cross the blood-brain barrier and be converted into dopamine in the brain. L-DOPA exhibits anti-hyperalgesic effects and holds potential in Parkinson’s disease research, and it can also be used to induce Parkinson’s disease models.

Rasagiline (AGN1135) is an inhibitor of monamine oxidase used as adjunctive therapy in combination with levodopa and carbidopa in the management of Parkinsons disease.

Tolcapone (Ro 40-7592) is a catechol-O-methyltransferase inhibitor employed as an adjunctive therapy with levodopa and carbidopa in the treatment of Parkinson's disease.

L-DOPA-2,5,6-d3 is a deuterated isotope of L-Dopa for isotope tracing. L-DOPA is an orally active metabolic precursor of the neurotransmitter dopamine, capable of crossing the blood-brain barrier and converting to dopamine within the brain. It exhibits anti-hyperalgesic effects and is utilised in Parkinson's disease research.